Betta Pharma Signs $135 Million Deal for China Rights to Two Immunotherapies
publication date: Jun 22, 2020
Hangzhou Betta Pharma signed a $135 million deal to in-license China rights for two immunotherapies from Agenus of Massachusetts. The two candidates are balstilimab, an anti-PD-1, expected to file for US approval this year, and zalifrelima, an anti-CTLA-4. They are being tested to treat refractory or metastatic cervical cancer. Betta will pay $35 million upfront ($15 million in cash and a $20 million equity investment) plus $100 million in potential milestones, and it will make royalty payments on net sales. More details....
Stock Symbols: (SHZ: 300558) (NSDQ: AGEN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.